Compare Ginkgo Bioworks Holdings Inc (DNA) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs HubSpot Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.08 (market cap $590.53M), while HubSpot Inc trades at $215.95 (market cap $10.73B). The key difference: HubSpot Inc is far larger — about 18.2× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| DNA | HUBS | |
|---|---|---|
Market Cap | $590.53M | $10.73B |
Sector | Health | Technology |
52-Week High | $16.14 | $560.90 |
52-Week Low | $5.48 | $170.39 |
Enterprise Value | $627.78M | $9.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
HubSpot (HUBS) trades at $217.59, up 4.87% with a bullish technical signal. The stock shows strong revenue growth, reaching $3.13B in 2025, and has beaten earnings estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with an 80.85% buy rating and a consensus price target of $273.53. Recent news highlights AI-driven expansion and customer growth, with the company hosting an Analyst Day in September 2026.
The outlook for HUBS is favorable due to robust fundamentals and AI integration, but risks include high valuation multiples and competitive pressures. Upside potential exists if earnings growth continues, though investors should monitor margin expansion and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
